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Abstract Osthole has been found to restore bone mass in
preclinical osteoporotic models. In the present study, we
investigated the effects of osthole on bone fracture repair in
mice. Adult C57BL/6 mice were subjected to transverse
femoral fractures and administrated orally with 20 mg/kg
osthole and vehicle solvent daily from week 1 post-oper-
ation. Fracture callus were analyzed by plain radiography,
micro-computed tomography, histology, molecular imag-
ing and immunohistochemistry and tartrate-resistant acid
phosphatase staining. Results demonstrated that osthole
treatment enhanced removal of cartilage and bony union
during reparative stage without significant interfering on
remodeling process. In vivo molecular imaging showed
bone formation rate of the treatment group was almost
twofold of control group at week 2 post-operation. Osthole
augmented the expression of alkaline phosphatase and
collagen type X in hypertrophic chondrocytes as well as
expression of bone morphogenetic protein-2, osteocalcin
and alkaline phosphatase in osteoblastic cells, indicating it
promoted mineralization of hypertrophic cartilage and
woven bone growth simultaneously during endochondral
healing. In summary, osthole promotes endochondral
ossification via upregulation of maturation osteogenic
marker genes in chondrocytes and subsequently accelerates
fracture repair and bony fusion.
Keywords Osthole  Fracture healing  Endochondral
ossification  Bone mineral density  Molecular imaging
Introduction
Bone regeneration takes place in consequence of osteo-
porotic fragility, trauma or orthopedic surgery [1–3].
Osteoporotic facture in elder people can lead to further
disability and early mortality. It has become a significant
global health problem since prevalence of osteoporosis is
estimated over 200 million people worldwide and is con-
tinuously growing with aging of population [4, 5]. These
fractures can be associated with morbidity like impaired
healing, delayed union or non-union, leading to extra pain,
prolonged hospital stay and convalescence period.
Drugs suppress osteoclastic bone resorption especially
bisphosphonates (BPs) are widely used in current standard
treatment of osteoporosis [6]. However, the efficacy of
anti-resorptive agents on growth and recovery of bone
mineral density (BMD) is limited, which is considered less
than 2 % every year [7]. Besides, long-term treatment of
these agents was reported not only reduce osteoclasts
number but also significantly reduce osteoblasts number
and subsequent bone formation [8]. Moreover, further
clinical concern arises when fragility fracture occurred in
osteoporotic patients who usually have poorer healing
ability. Accumulating clinical reports suggested that higher
risks of atypical femur fractures and jaw osteonecrosis
were associated with prolonged BP treatment [9, 10].
Numerous experiments on animal models also indicated
BP administration delay callus remodeling and may have
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negative effect on bone healing process [11–13]. There-
fore, new therapeutic agents that can inhibit bone resorp-
tion as well as facilitate bone repair are needed, which are
more desirable in treatment of fragility fracture caused by
osteoporosis.
Medicinal plants have been suggested as large source of
potential agents against osteoporosis [14]. Osthole is a
naturally derived coumarin, which is found medicinal
plants such as Cnidium monnieri, Angelica archangelica
and Angelica pubescens. Total coumarins extract from C.
monnieri fruit was reported be effective for prevention of
bone loss in both ovariectomy and glucocorticoids-induced
osteoporosis rat models [15, 16]. It was then suggested that
the anti-osteoporotic effect was attributed to the major
bioactive coumarin osthole, and this chemical was as
effective as 17b-estradiol in suppressing bone loss in
ovariectomized (OVX) rats [17, 18]. The anti-osteoporotic
effect of osthole was further confirmed by Tang et al. [19],
and they also suggested that osthole had anabolic effect
since local injection of osthole increased new bone for-
mation in mouse calvaria. Additionally, studies in cell
models indicated osthole-induced osteoblastic differentia-
tion by upregulation of osteogenic genes such as osteo-
calcin (OCN), alkaline phosphatase (ALP) and collagen
type I (Col-I) by activation of bone morphogenetic proteins
(BMP) pathway [19–21]. These experimental findings all
suggested that osthole is a potential anabolic agent appli-
cable for both treating osteoporosis and enhancing bone
formation. In the present study, we examined the effect of
osthole on bone healing process using a mouse mid-shaft
femoral fracture model and investigated the possible
mechanism comparing to the previous in vitro studies.
Materials and Methods
Animal Model
C57BL/6 mice were obtained from the Laboratory Animal
Services Center of the Chinese University of Hong Kong.
The animal study was approved by Animal Experimenta-
tion Ethics Committee (12/002/DRG-5). All mice were first
acclimatized and housed at the research animal laboratory
during the experimental period. Open osteotomy at femur
diaphysis modified from previous study [22] was per-
formed on 12-week-old male C57BL/6 mice to establish a
stable femoral open fracture model. Briefly, mouse weight
of 25–30 g was general anaesthetized with intraperitoneal
injection of ketamine (67 mg/kg body weight) and xylazine
(13 mg/kg body weight). After shaving and sterilization of
right leg, a lateral incision was made and a 25-gauge needle
was inserted retrograde into the intramedullary canal from
knee articular surface for internal fixation. Diaphysis of the
femur was exposed and an air pen driven oscillating saw
(Synthes Holding AG, Zuchwil, Switzerland) was used to
create a transverse mid-shaft fracture under irrigation with
sterile 0.9 % saline solution. Digital X-ray radiography was
taken to confirm the alignment of the bone. Absorbable
sutures were used to close the intramuscular septum and
skin incisions.
Drug Administration and Specimen Harvest
Osthole (UHPLC 98 %) used in animal administration was
purchased from LKT Laboratories, Inc. (MN, USA). Ost-
hole reagent was freshly prepared by dissolution with
0.5 % (v/v) Tween 80 (Sigma-Aldrich, MO, USA) in dis-
tilled water. Three dosages of osthole, 5 (low), 20 (middle)
and 50 (high) mg/kg of body weight (derived from Li et al.
[18]) were given to mice by daily oral gavage from week 1
(day 7) post-osteotomy until euthanasia, and mice in con-
trol group were fed with vehicle solvent only. Body
weights were monitored throughout whole experimental
process.
Animals in control and treatment groups were subject to
X-ray radiography, micro-computed tomography (l-CT),
histology and molecular imaging assessments. Fractured
and contralateral femurs were harvested at the end of
experiment at week 2, 3 and 4 post-operation. Soft tissues
were removed from the operated and contralateral femurs.
The specimens were fixed within 4 % paraformaldehyde
(Life Technologies, NY, USA) solution for 24 h. Internal
fixation needle was removed from the intramedullary
cavity and the femur specimens were stored in 70 %
ethanol for l-CT and histologic processing.
Plain Radiography
Serial radiographs were conducted throughout the experi-
ment period from osteotomy surgery (week 0) to
euthanasia. Radiographs of animals from control, low,
middle and high groups were taken weekly from week 0 to
week 4 using the digital radiographic function of in vivo
Multispectral FX PRO system (Carestream Health, NY,
USA). The callus area and pixel intensity of the fractured
femur was measured at each time point, by outlining the
callus by region of interest (ROI) (shown with pink dotted
line in Fig. 1a) with Carestream Molecular Imaging (MI)
Software.
In vivo and Ex vivo Molecular Imaging
In vivo bone growth were imaged and analyzed with two
commercial fluorescent in vivo bisphosphonate imaging
probe OsteoSense 680 Ex (OS680) and OstenSense 800
(OS800) (PerkinElmer, MA, USA) with two distinct
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wavelengths modified from suggested protocol and previ-
ous study [23]. Briefly, anesthetized mice were injected
retro-orbitally with dissolved fluorescent probes (10 nmol/
kg) 48 h before imaging. Hair was removed from the hind
legs. Florescent signals and X-ray images were captured by
combination of multispectral fluorescence and digital
radiograph function of in vivo Multispectral FX PRO
system. After anesthesia, signals of injected Os680 were
detected in vivo with excitation wavelength at 650 nm and
emission at 700 nm at week 2, while Os800 was injected
and detected (excitation 760 nm/emission 830 nm) at week
3. At week 4, both florescent signal of Os650 and Os800 in
both sides of femur were measured ex vivo after femurs
were harvested. Florescent and radiographic images
obtained were overlayed and analyzed with Carestream MI
Software. ROIs of same area were selected from operated
and contralateral femurs versus surrounding skin (as
background signal). Os signal intensity of fractured right
femurs was normalized by intensity of contralateral side.
Micro-Computed Tomography (lCT) Analysis
Harvested and fixed bone specimens of week 2, 3 and 4
were subject to lCT scanning using MicroCT40 (Scanco
Medical, Switzerland). The scan range covered a 6 mm
thickness with the center at fracture line at an isotropic
resolution of 10 lm. The contoured ROI were selected
from 2D CT images, and 3D reconstruction were per-
formed with a low-pass Gaussian filter (Sigma = 1.2;
Support = 2). Low attenuation threshold of 130 and high
attenuation threshold of 250 was set to distinguish newly
form mineralized callus from old cortical bone referring to
previous study [24]. Quantitative analysis was performed
covering 250 slices above the fracture line and 250 slice
Fig. 1 Osthole administration accelerated fracture healing process.
Mice received femur osteotomy were oral administrated with 0
(control), 5, 20 and 50 mg/kg body weight of osthole from
postoperative week 1. a Representative serial radiographs of one
mouse from every group from week 0–4; dotted line callus ROI for
analysis. b, c Area and pixel intensity of callus ROIs (mean ± SD,
n = 10); two-way ANOVA followed by Tukey’s test, *p\ 0.05,
**p\ 0.01, ***p\ 0.001 compared to control group
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below. Callus total volume (TV) identified the volume of
newly formed tissues (callus) and low-density bone volume
(BVl) identified the volume of newly formed mineralized
tissue in callus. TV and BVl were both calculated by
reduction of the volume in fractured femur with the volume
of the contralateral cortical bone. Tissue mineral density
(TMD) measured the volumetric density of calcium
hydroxyapatite (CaHA) in total tissue including both newly
formed callus and old cortical bone; bone mineral density
(BMD) measured volumetric density of CaHA in total
mineralized tissue (bone). TMD and BMD were expressed
as percentage of contralateral intact bone.
Histology and Immunohistochemistry
Fixed bone specimens were decalcified with calcium
chelating solution (0.5 M EDTA/NaOH, pH 7.5) for
2 week. Decalcified bones were then dehydrated and
embedded in paraffin wax using Leica EG Embedding
Center (Leica Microsystem, Wetzlar, Germany). Paraffin
blocks were sectioned into 5 lm slices and mounted on
glass slides. The sections were deparaffinized and triple
stained with hematoxylin and eosin (H&E) along with
alcian blue (Sigma) specific for cartilage tissue [25]. The
histomorphometry analysis was performed by a blinded
observer using Zen2012 (Zeiss, Oberkochen, Germany).
For immunohistochemistry (IHC), sections were
deparaffinized and rehydrated in phosphate buffered saline
(PBS). After endogenous peroxidases were quenched with
3 % H2O2/MeOH, antigen retrieval was performed
according to the suggestions from primary antibody pro-
ducer. After nonspecific binding blocked with UltraVision
protein block (Thermo Scientific, MA, USA) or incubation
solution for 30 min, sections were incubated overnight at
4 C with diluted solution of primary antibody against
BMP-2, ALP, OCN, Col-I, Col-X Cathepsin K (CTSK)
(Abcam, Cambridge, UK) and solution without antibody as
negative control. The sections were then incubated with
horseradish peroxidase conjugated secondary antibody
(Santa Cruz biotechnology, CA, USA) for 30 min at room
temperature. IHC signal was developed with Liquid
DAB ? Substrate Chromogen System (Dako, CA, USA),
counter-stained with hematoxylin and subjected to blinded
evaluation.
Tartrate-Resistant Acid Phosphatase (TARP)
Staining
Deparaffinized sections were stained using Sigma Acid
Phosphatase, Leukocyte (TRAP) Kit following the
instructions provided. Briefly, slide was firstly incubated in
Solution A (125 lg/ml naphthol AS-Bl phosphoric acid,
tartrate/acetate buffer) at 37 C protected from light for
45 min and then subsequently incubated in Solution B
(70 lg/ml diazotized Fast Garnet GBC base in tartrate/
acetate buffer) for 5 min to develop the color. After
counterstaining with hematoxylin, sections were mounted
by aqueous mounting medium and evaluated microscopi-
cally within 1 day.
Statistical Analysis
Statistical analysis was conducted using GraphPad Prism
5.0 (GraphPad Software, CA, USA) software and Excel
(Microsoft, CA, USA). All data were obtained from 6 to 10
individual mice in control or treatment groups. Mean and
standard deviation values (mean ± SD) were calculated for
all statistically analyzed parameters. The differences
between groups were analyzed using ANOVA with Tur-
key’s post hoc test or unpaired Student’s t tests. The
p value less than 0.05 was considered statistically
significant.
Results
Osthole Administration Accelerated Fracture
Healing Process
To determine the effect of osthole gavage dosage on mice
fracture repair, mice were treated with vehicle solvent and
three dosage of osthole. Mice body weight and fractured
bone morphology from 1 to 4 weeks were monitored and
analyzed. Body weight in each group did not significantly
change throughout experimental period. Serial radiographs
of control and low-dose group demonstrated very similar
morphology changing pattern (Fig. 1a). Clear callus con-
tour could be defined at week 2 and at week 3 the callus
became more radiopaque with similar size as compared
with that of week 2. At week 4, callus size was found
obviously reduced. Whereas in group treated with middle
and high dose, the callus size at week 3 was apparently
reduced as compared with week 2, which was much
smaller than that in control group; and the callus size was
further reduced at week 4 (Fig. 1a). The area and pixel
intensity of callus ROIs was quantified and used to estimate
the volume of callus and the quantity and density of bone in
it (Fig. 1b, c). Callus area in middle and high group was
significantly smaller than that of control group
(5.69 ± 1.09 mm2) by 43.65 and 36.17 % of control,
respectively. The intensity of callus ROIs at week 2 in
middle and high group (0.2310 ± 0.0204 and
0.2320 ± 0.0311, respectively) was slightly higher than
average control value (0.2016 ± 0.0228) with a statistical
significance. Since middle and high dose of osthole did not
have significant difference, middle dose (20 mg/kg/day)
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was selected as the optimum dose and applied in further
assessments.
Osthole Increased Bone Mineral Density
and Promoted Bony Callus Formation
Reconstruction of lCT scan slices allowed a visual eval-
uation and comparison of fracture callus in control and
osthole-treated mice. In the representative 3D image of
control group, there was large gap between bony bridge in
callus at week 2; the newly formed bone had not fully
bridged until week 3, whereas higher proportion of min-
eralized bone in callus was observed in osthole group at
week 2. Fractured gap had already completely surrounded
by hard callus at week 3, and at week 4, the fractured bone
was further remodeled and restored to original shape and
texture (Fig. 2a). Analytical results of 3D radiography were
generally consistent with the results from plain radiogra-
phy. Average BVl/TV of control group reached peak value
at week 3 and slightly decreased at week 4, similar to the
trend of callus intensity obtained from analysis of 2D
radiographic images; BVl/TV of osthole was significantly
higher at week 2 and 3 by 45.27 and 15.87 %, respectively
(Fig. 2b). TMD and BMD showed a steady increase along
time in both groups, while comparing between groups
demonstrated that osthole administration markedly raised
TMD of fractured femur at each time point (Fig. 2c); BMD
of treated mice was significantly higher than control at
week 3 and 4 (Fig. 2d).
Since radiographic evaluations were not able to identify
cartilage and other soft tissues, histological sections of
fractured bone were labeled with both cartilage and bone
and histomorphometric analyses were performed. Histol-
ogy results complemented lCT images: at week 2 post-
fracture, control calluses contained similar amount of car-
tilaginous and bony tissues; at week 3 cartilages persisted
in calluses; and by week 4 cartilages had diminished and
callus size reduced indicating remodeling. Whereas osthole
Fig. 2 Osthole promoted callus bridging and increased bone density.
Fracture calluses from control and osthole-treated mice were
harvested at week 2, 3 and 4 post-osteotomy. a Representative 3D
images of fractured femur from both groups at week 2, 3 and 4 (Bar
1 mm). b–d BVl/TV, TMD, BMD (mean ± SD, n = 6); one-way
ANOVA followed by Tukey’s test, *p\ 0.05, **p\ 0.01
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group exhibited obviously smaller total surface area of
cartilaginous tissues at week 2, the callus had fully bridged
with woven bone by week 3; bony callus was further
remodeled and the cortical fracture gap was united
(Fig. 3a). Histomorphometric analysis showed the bony
callus area in osthole group was significantly larger than
control group, while the cartilaginous callus area was much
smaller at week 2 post-operation (Fig. 3b); the woven bone
surface area in treatment group became smaller than con-
trol and the cartilaginous tissue almost diminished from
callus at week 3 (Fig. 3c).
Osthole Enhanced Osteoblastic Bone Formation
and Promoted Endochondral Ossification
Osteosense (Os) was used to localize neo bone growth and
to quantify growth rate in living animals. Due to long half-
time of Os probes in bone and their narrow excitation and
emission wavelength range, mice with osteotomy were
dual-labeled with Os680 and Os800 at week 2 and 3,
respectively. Positions of new bone formation were map-
ped in living animals by florescent signals, and bone
growth rate was quantified by signal intensity ratio and
compared between control and osthole group (Fig. 4a). The
bone formation rate at week 2 in treatment group was
markedly higher than that in control group by 80.72 %,
which dropped at week 3 but still higher than control value
by 25.95 % (Fig. 4b). Florescent signals of both probes
were captured ex vivo after euthanasia at week 4 to elim-
inate the possible interference of soft tissues. The ex vivo
florescence pattern of two probes more accurately
demonstrated the new bone formation inside calluses.
Os680 signals distributed around two ends of the callus,
while Os800 signals located at the center of the callus near
Fig. 3 Osthole enhanced
cartilage removal in reparative
phase. Fracture calluses were
harvested and decalcified at
week 2, 3 and 4 post-osteotomy.
Callus sections were tripled
stained with alcian blue
(cartilage) and H&E.
a Representative images
showed cartilaginous (blue) and
mineralized (pink) callus from
both groups at week 2, 3 and 4
(Bar 500 lm). b, c Surface area
of cartilage and woven bone in
callus at week 2 and 3
(mean ± SD, n = 6 or 8);
unpaired Student t test,
*p\ 0.05, **p\ 0.01,
***p\ 0.001 (Color
figure online)
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fracture line (Fig. 4c). Average values of fractured/con-
tralateral fluorescent intensity ratio were obtained from
both lateral and central views. Fluorescent intensity ratio of
both Os680 and Os800 were relatively lower compared to
their in vivo values, whereas for both probe the ex vivo
intensity ratios of osthole group were significantly higher
than those of control group (Fig. 4d).
Immunohistochemistry (IHC) of osteogenic marker
were performed and compared between control and treat-
ment group at week 2. As shown in Fig. 5, BMP-2 mainly
expressed in osteogenic cells surrounding woven bones;
ALP specifically expressed around hypertrophic cartilagi-
nous tissues and newly formed bone tissues; OCN
expressed throughout the whole callus which is highly
expressed in osteogenic cells but also found in bone matrix.
In osthole-treated group, expression of BMP-2, ALP and
OCN was all observably higher than those in control group.
Osthole treatment also evidently increased OCN expression
in newly formed bone matrix but not affected cortical bone.
Col-X and Col-I were also accessed by IHC at week 2. Col-
X was only highly expressed in hypertrophic chondrocytes
and cartilaginous matrix, and Col-I expression were found
mainly in soft tissues but also hard tissues in callus.
Interestingly, osthole administration dramatically promoted
the expression of Col-X at week 2 but have no marked
effect on Col-I expression (data not shown) (Fig. 5).
Osthole Had No Effect on Osteoclast Number
and Did Not Delay Callus Remodeling
To examine the influence of osthole administration on
osteoclastogenesis during fracture callus remodeling,
TRAP staining of callus histological sections at week 3 and
week 4 was performed and IHC staining of osteoclastic
Fig. 4 Osthole increased mineralization rate of callus. Mice in
control and osthole group were both injected with Os680 and Os800
and subjected to in vivo imaging at week 2 and 3, respectively, and
femurs were harvested after euthanasia at week 4 and subject to
ex vivo imaging for both probes. a, c Representative overlay images
of X-ray and florescent signals of both groups taken in vivo (a) and
ex vivo (c), dotted line: the ROI for intensity quantification. b,
d Intensity ratio (fractured/contralateral) of Os680 and Os800
(mean ± SD, n = 6); unpaired Student t test, *p\ 0.05,
***p\ 0.001
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marker CTSK was conducted to further confirm the results.
Figure 6a showed that osteoclasts distribution of two
groups was similar at both time points. At week 3, TRAP
positive osteoclasts located near fracture site with high
density, at the surface of newly formed woven bone. By
week 4, osteoclasts abundance markedly dropped and
Fig. 5 Osthole upregulated osteogenic and chondrogenic markers
during endochondral bone formation. Fracture calluses were har-
vested and decalcified at week 2 post-osteotomy. Callus sections were
blotted with BMP-2, ALP, OCN, Col-X antibody and negative control
and then counterstained with hematoxylin. Representative images
showed both cortical bone (CB) and newly formed cartilage/bone
tissues (n = 4–6; Bar 50 lm; CB cortical bone)
Fig. 6 Osthole did not affect osteoclasts abundance and remodeling
progress in callus. Fracture calluses from control and osthole-treated
mice were harvested at week 3 and 4 post-osteotomy. a Representative
TRAP staining and immunohistochemical staining of CTSK; small
rectangular indicated area enlarged, CTSK immunostainings were
taken at close position from the sample specimen (n = 4, Bar 50 lm)
b TRAP positive osteoclasts number per mm2 fracture callus surface
area in control and osthole group (mean ± SD, n = 4). c Quantifica-
tion of low-density bone volume at week 3 and 4 (mean ± SD,
n = 6); unpaired Student t test, **p\ 0.01
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osteoclasts distributed relative evenly in the whole callus.
CTSK immunostaining demonstrated similar osteoclasts
number and distribution. Quantification of the osteoclasts
number expressed as cell number per unit callus surface
area (mm2). Osteoclasts number was 101 ± 14 (Con)
compared to 103 ± 11 (Ost) at week 3; and 52 ± 9 (Con)
compared to 47 ± 7 (Ost) at week 4, which did not show
significant difference between control and treatment group
(Fig. 6b).
Plain X-ray and l-CT imaging of bony callus in osthole
group both demonstrated reduction of callus size from
week 3 to week 4, suggesting callus remodeling was not
delayed after osthole gavage (Figs. 1a, b, 2a). Low-density
newly formed bone volume was 11.18 ± 1.85 (week 3)
and 6.80 ± 1.35 (week 4) mm3 in control group; and
9.04 ± 2.43 and 4.89 ± 0.57 mm3 in osthole group, the
volume in osthole group was significantly lower than that
in control group at week 4 (Fig. 6c). The average reduction
volume of woven bone in control and osthole group was
4.38 and 4.15 mm3, respectively, which was close to each
other, indicating the remodeling efficacy was not signifi-
cant affected.
Discussion
Osteoporotic fractures are among the most prevalent health
conditions in elder population. Although BPs are used with
satisfactory results for restoring bone density in osteo-
porosis therapy, their application on patients with fragility
fractures is contentious having been reported to cause
compilations during bone repair and to delay healing pro-
gress. Therefore, anabolic agents that stimulate bone for-
mation, such as BMP-2,-7 and parathyroid hormone (PTH),
are suggested enhancing bone healing process, reducing
fracture-associated complications and hence benefiting
normal and osteoporotic fracture repair when applied alone
or combined with BPs [26]. However, in spite of the
potency of these anabolic growth factors, they have defi-
ciencies like drug delivery limitation, safety concerns and
cost-efficient issues. Safer anabolic agents with substantial
cost and easy way of administration are thereby still
required. Osthole has been shown to stimulate local bone
formation [19] and inhibit osteoporotic bone loss [18, 19]
as well, which makes it an ideal potential candidate for
osteoporotic fractures treatment. We hypothesized osthole
is an osteoanabolic agents that promote endochondral bone
growth in fracture repair.
Given the fact that osthole injection accelerated osteoid
formation and mineralization in mouse calvaria surface
[19], we hypothesized that oral gavage of osthole enhance
osteoblastic bone formation in fracture healing. Endo-
chondral fracture repair is nevertheless a complex process
that involves a serial of biological events requiring inter-
action of different tissue and cellular systems other than
osteogenic cell lineages. Hence, osthole was given from
week 1 post-fracture to reduce the effect of osthole on early
events in inflammatory phase. Healing progress was eval-
uated from 1 to 4 weeks covering the whole reparative
phase and the beginning of the prolonged remodeling
phase. Three different dosages in this study were adapted
from oral application of osthole on rat osteoporotic model
[18]. Area and pixel intensity of ROIs were quantified for
estimating the volume and average mineral density of
callus accordingly [27], to study the dose-dependent effect
relationship of osthole on fracture repair. Results showed
higher mineral density and smaller volume of callus in
middle and high dose, whereas the middle and high group
did not show significantly difference. This is probably
because of the low oral bioavailability of osthole which
limit the actual absorption [28, 29]. Middle dose was
selected for the following assessments in this study.
Our radiographic and histomorphometric analyses at
week 2 and 3 demonstrated a comprehensive evaluation of
fracture healing process that showed clear acceleration of
bony callus bridging and removal of fibrocartilage/cartilage
by osthole treatment during reparative progress. It is worth
mention that osthole not only increased the proportion of
bone content in callus at week 2 and 3, but also signifi-
cantly raised the average BMD of newly formed bone
tissues. This result agrees with the previous reports that
oral intake of osthole improved BMD and biomechanical
properties in osteoporotic animal model [18, 19]. Near-
infrared florescence labeled pamidronate probes (Os) allow
to in vivo localize new bone formation and measure ossi-
fication rate in living animal. It has also been well estab-
lished that bisphosphonates deposit into areas of new bone
formation [30]; also near-infrared florescence molecules
have been widely used in in vivo imaging for good photon
propagation through living tissue and high signal to back-
ground ratio [31]. Furthermore, due to narrow excitation/
emission wavelength range of Os probes and their long
half-time of in bone, fractured femurs were dual-labeled
and examined with Os680 and Os800 at week 2 and 3,
respectively; and ex vivo signals of both probes were taken
after bones harvested from animals. Average ossification
rate in callus treated with osthole at week 2 was almost
twice as much as control, which was close to the osthole-
induced increasing of mineral appositional rate obtained by
calcein labeling [19]. Mineralization rate of osthole group
dropped remarkably at week 3, indicating end of reparative
phase and transition to remodeling phase. It was still higher
than control group in average by 25.95 %, but statistical
significance was not observed because of large ingroup
variations. Intensity ratio calculated from ex vivo signals
were much lower compared to in vivo values for both
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probes in both group. It was probability because flores-
cence molecules faded with time and some probes had
dissolved back to surround fluid due to bone remodeling.
Nevertheless, osthole-treated callus still showed significant
higher ex vivo ratio than control ones.
Expressions of osteogenic-related proteins were exam-
ined with IHC to determine the mechanism by which ost-
hole accelerate fracture repair. At week 2 post-osteotomy,
both cartilage and woven bone existed in calluses from
both control and treatment group. In hypertrophic chon-
drocytes and matrix, both Col-X and ALP were much
higher expressed in osthole group than control group. Both
of them are terminal differentiation markers for hyper-
trophic chondrocytes [32–34], indicating more rapid cal-
cification in cartilage matrix. ALP also higher expressed in
osteoblastic cells surrounding new bone islands, along with
growth factor BMP-2 and another osteogenic marker OCN,
all suggested more active woven bone growth rate in new
bone area. Upregulation of BMP-2, ALP and OCN in
osteoblasts inside callus echoed with the results obtained
from in vitro osteoblastic cell models, while on the other
hand, there was no observable difference in expression of
Col-I between osthole and control group, which was not
consistent with the findings on primary osteoblasts and
osteoblast-like cell lines [19–21]. Col-I is the main colla-
gen type in bone developing cross-linkage, and the effect
of osthole on total Col-I content was probably not signifi-
cant enough, even if osthole administration did invoke the
expression in chondrocytes and osteoblasts. Hypertrophic
chondrocyte formation in soft callus is an essential process
of endochondral ossification in fracture healing. Hyper-
trophy of chondrocyte can be mediated by b-catenin/
Runx2/smad pathway with downstream expression of Col-
X [35]. Osthole has been reported to activate b-catenin,
Runx2, smad1/smad5 in osteoblastic cells [19, 21]. Addi-
tionally, osthole-induced BMP-2 upregulation might also
facilitate in early stage of chondrocyte hypertrophy [36].
Together, IHC results indicated that during reparative
phase osthole enhances mineralization of hypertrophic
cartilage as well as woven bone formation by augmenting
expression of Col-X (chondrocyte maturation marker) and
osteogenic markers.
Our study also demonstrates that osthole has no signifi-
cant effect on formation and activity of osteoclasts during
remodeling stage. Osthole gavage maintained the number of
osteoclasts and osteoclastic bone resorption from week 3 to
week 4. In addition, digital radiography shows advanced
remodeled callus in both size and texture at week 4 in
treatment group. This result is unexpected because inhibitory
effect of osthole on osteoclastogenesis was reported in both
osteoclast cell culture and osteoporotic rodent [19, 37].
Considering osteoclastogenesis is highly modulated by
osteoblastic cells and several osteoblast secreted proteins
bind to osteoclast surface receptor directly enhancing bone
resorption [38, 39], it is likely that osthole-activated
osteoblastic activity may also stimulate osteoclastic activity
that overcome inhibitory effect of osthole on osteoclasto-
genesis. Although previous studies suggest that osthole
exhibits BP-like osteoclastic inhibitory effect, the histolog-
ical changes of osthole-treated callus is totally different from
alendronate-treated fracture healing. Alendronate maintains
callus size and increasemineral density [11, 40], but does not
provide stimulation effect on osteoblasts.
On the other hand, considering the effects of osthole on
BMD and strength of untraumatized cortical and cancel-
lous bone and more dramatic promotive activity on bone
healing and union, the action of osthole on bone is similar
to the anabolic activities of PTHs [41–43]. Furthermore,
both of their mechanisms on osteoblast differentiation are
suggested closely associated with b-catenin signaling
[44–46]. Consequently, osthole may share the similar
potential as PTH on preventing fragility fracture and
enhancing healing of fractures when normal process fails in
patients with osteoporosis [43] and can be applied in pro-
longed therapy as BPs to restore BMD. A limitation of this
study is it mainly focused on endochondral ossification
stage, the effects of osthole on early events in fracture
healing including angiogenesis and chondrogenesis should
also be evaluated in detail to realize complete mechanism
of application of osthole on fracture healing.
In conclusion, this study demonstrated that oral admin-
istration of osthole promotes healing progress by enhancing
endochondral ossification in reparative phase with no sig-
nificant influence on remodeling. We suggest that osthole is
a potential osteoanabolic agent with which can be applied
on osteoporotic fracture in long term with economical cost.
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